Ischemic heart diseases are the most frequent diseases in the western world. Apart from Interleukin (IL-)1, inflammatory therapeutic targets in the clinic are still missing. Interestingly, opposing roles of the pro-inflammatory cytokine IL-23 have been described in cardiac ischemia in mice. IL-23 is a composite cytokine consisting of p19 and p40 which binds to IL-23R and IL-12Rβ1 to initiate signal transduction characterized by activation of the Jak/STAT, PI3K and Ras/Raf/MAPK pathways. Here, we generate IL-23R-Y416FΔICD signaling deficient mice and challenged these mice in close-and open-chest left anterior descending coronary arteria ischemia/reperfusion experiments. Our experiments showed only minimal changes in all assayed parameters in IL-23R signaling deficient mice compared to wildtype mice in ischemia and for up to four weeks of reperfusion, including ejection fraction, endsystolic volume, enddiastolic volume, infarct size, gene regulation and α smooth muscle actin (αSMA) and Hyaluronic acid (HA) protein expression. Moreover, injection of IL-23 in wild-type mice after LAD ischemia/reperfusion had also no influence on the outcome of the healing phase. Our data showed that IL-23R deficiency has no effects in myocardial I/R.
The immune system and their cytokines contribute to the healing processes after myocardial infarction 1 . Apart from Interleukin (IL-)1, inflammatory therapeutic targets in the clinic are still missing 2 . It is, however, in most cases still unclear to which extent different cytokines are involved in positive or negative remodeling of the heart after myocardial infarction in preclinical models of acute heart failure. Some cytokines having even positive and negative effects depending on the time after myocardial infarction, as exemplified by Interleukin (IL-)6, which is protective in the early phase but becomes detrimental if chronically produced 3 . For the closely related IL-23 different outcomes after myocardial infarction have been described in mice. Savvatis et al. reported a protective role of IL-23 signaling in a murine model of permanent occlusion of the left anterior descending artery (LAD). They showed that IL-23p19 deficient mice had an overall reduced survival rate, higher expression of inflammatory cytokines and infiltration of inflammatory cells accompanied by impaired healing process 4 . In opposite, Yan et al. showed that infarct size in IL-23p19 deficient mice was reduced and overall survival was increased after myocardial infarction (permanent ligation) compared to wild-type mice 5 . This finding was supported by studies in rats. Here, rats injected with recombinant IL-23 after acute ischemia/reperfusion had increased infarct sizes and upregulation of inflammatory cytokines, whereas blockade of IL-23 by a neutralizing anti-IL-23 antibody resulted in reduced infarct sizes and less apoptotic cells 6 . The reason for these different phenotypes remain unclear but might be related to the complex biology of IL-12-type cytokines. The IL-12 family of cytokines is comprised of IL-12, IL-23, IL-27, IL-35 and IL-39 7 . These cytokines consist of soluble heterodimers formed by α and β subunits. The cytokine α chain IL-23p19 is structurally related to IL-6 and forms complexes with the soluble receptor subunit IL-12p40 (β chain). IL-39 (also named IL-X) is also composed of IL-23p19 but forms a complex with EBI3 which is also engaged with p28 in IL-27 8 . IL-23 signals via the heterodimeric receptor complex IL-23R:IL-12Rβ1, in which the IL-23R is regarded as the only signal-transducing component of the IL-23 receptor complex 9 . The receptor complex of IL-39 is not known, however, combinations of IL-23R:gp130 were recently proposed 8, 10 . IL-23 activates mainly STAT3 but also STAT1, 4 and 5 11 . Some of the pro-inflammatory functions of IL-23 are related to the induction of terminal differentiation and proliferation of IL-17-producing CD4 + T helper (T H 17) cells 12 . Consequently, IL-23 (p19) or the IL-23 receptor (IL-23R) deficient mice are resistant to autoimmune and inflammatory disorders, such as experimental autoimmune encephalomyelitis 13 , collagen-induced arthritis 14 and inflammatory bowel disease (IBD) 15, 16 . A number of cell types express IL-23 receptor chains, including CD4
+ T cells of the T H 17 lineage, γδ T cells, macrophages, dendritic cells, and innate lymphoid cells 17, 18 . Using site-directed mutagenesis and deletion variants of the murine and human IL-23R, we have previously defined canonical and non-canonical STAT and MAPK binding/activation sites within the murine IL-23R. The membrane-proximal Y416 in murine IL-23R is involved in the activation of PI3K/AKT and the MAPK pathway upon stimulation with IL-23 19 .
Here we generated a novel IL-23R-Y416FΔICD signaling deficient mice and challenged these mice in myocardial ischemia/reperfusion. These mice are characterized by the amino acid exchange Y416F and deletion of most of the intracellular domain beginning at amino acid residue 433 to abrogate canonical and non-canonical STAT binding/activating sites of the intracellular domain of the IL-23R. Surprisingly, these mice revealed that IL-23R signaling plays no role in the healing phase of myocardial infarction after ischemia/reperfusion.
Results

Generation of IL-23R signaling deficient mice.
In order to analyze the role of IL-23 signaling in left anterior descending coronary arteria (LAD) ischemia/reperfusion, we generated mice with either defective AKT signaling or complete loss of signaling of IL-23. The intracellular domain of the IL-23R is coded by exon 10 and exon 11. The first tyrosine in the intracellular domain is responsible for AKT/ERK signaling and coded by exon 10. Moreover, canonical and non-canonical STAT and ERK signaling is mediated by amino acids coded in exon 11 (Fig. 1A ) 19 . First of all, we introduced a point mutation in exon 10, resulting in the amino acid exchange Y416F abrogating AKT signaling 19 and exon 11 was flanked by loxP sites. As a consequence floxed IL-23R-Y416F mice are defective for AKT signaling. Cre-mediated recombination resulted in deletion of exon 11 and abrogated STAT and ERK signaling. These mice are referred to as IL-23R-Y416FΔICD signaling deficient mice (Fig. 1B) . Deletion of exon 11 led to a shortened intracellular domain with 14 alternative amino acids coded by the former intron 11 until translation is stopped by a new stop codon (Fig. 1C) .
Here, IL-23R-Y416F mice were crossed with a CRE-deleter, which resulted in deletion of IL-23R exon 11 in the germline. Introduction of Y416F and the loxP sites in IL-23R-Y416F mice and deletion of exon 11 in IL-23R-Y416FΔICD signaling deficient mice was confirmed by genomic PCR (Fig. 1B,D,E) . Finally, we verified expression of wild-type-IL-23R, IL-23R-Y416F and IL-23RY416FΔICD by flow cytometry on spleen cells of IL-23R, IL-23R-Y416F and IL-23R-Y416FΔICD signaling deficient mice (Fig. 1F) , demonstrating that mutation and/or deletion of the intracellular domain did not disturb expression and presentation of the mutated and/or truncated IL-23R. Next, spleen cells from wild-type-IL-23R, IL-23R-Y416F and IL-23RY416FΔICD mice were stimulated with anti-CD3 and anti-CD28 mAbs in the presence or absence of TGF-β, IL-6 and IL-1β to induce IL-17 production. IL-23 signaling critically contributes to IL-17 production after CD3/CD28 and/or cytokine stimulation 20 , which was significantly reduced in spleen cells from IL-23R-Y416F and IL-23RY416FΔICD mice as compared to IL-23R (wild-type) mice (Fig. 1G) . Moreover, IL-17 is also produced after selective stimulation of CD3/CD28, albeit to a lesser extent. Importantly, in spleen cells from IL-23R-Y416F but to a higher degree from IL-23RY416FΔICD mice IL-17 expression was significantly suppressed (Fig. 1G ). Taken together, we generated and characterized a novel IL-23R signaling deficient knock out mouse.
Abrogation of IL-23 signaling has no effect on myocardial remodeling after closed-chest LAD ischemia/reperfusion. In a first step, closed-chest LAD ischemia/reperfusion (I/R) was induced in IL-23R (wild-type), IL-23R-Y416F and in IL-23R-Y416FΔICD signaling deficient mice ( Fig. 2A) . The closed-chest model was choosen because it reflects the symptoms of acute cardiac syndromes and thus mimics the condition of patients who appear after an acute myocardial infarction. LAD ligature was performed for all three genotypes and the chest and skin were closed again. To exclude that preconditioning could influence the ischemia/reperfusion results there was a break of 4 days between LAD operation and induction of ischemia. At postoperative day 4, ischemia for 60 min was induced followed by 3 weeks reperfusion. The heart function in mice was analyzed by echocardiography and the expression of α-SMA and HA was performed by immunostaining. The infarct size was quantified using Gomori's 1-step trichrome staining. Overall survival of all mouse groups was nearly identical with about 85% until 21 days after LAD ischemia/reperfusion (Fig. 2B) . The cardiac function, resulting from the analysis of LV ejection fraction, endsystolic volume and enddiastolic volume, was not statistically significant different between the three mouse strains as determined by echo-analysis at baseline and 3 weeks after I/R (Fig. 2C ). However, a trend towards lower ejection fraction and higher endsystolic volume and enddiastolic volume in the IL-23R-Y416FΔICD signaling deficient mice compared to IL-23R mice was apparent. Moreover, we analyzed myocardial wound healing and myofibroblast differentiation after 3 weeks of reperfusion. Importantly, the expression of α smooth muscle actin (αSMA), Hyaluronic acid (HA) and the infarct size demonstrated a significant increase in the IL-23R-Y416FΔICD signaling deficient mice compared to IL-23R mice (Fig. 2D-F) . No significant difference was observed in IL-23R-Y416F mice as compared to wild-type mice (Fig. 2D-F) .
The parameters for determining the LV cardiac function were also analyzed after 24 h and 4 d of reperfusion. As expected, after 24 h and 4 d of reperfusion no differences in ejection fraction, endsystolic volume and enddiastolic volume were observed (Fig. 3A,B) . Next, IL-23R-Y416FΔICD signaling deficient mice and IL-23R mice were sacrificed after ischemia and 24 h of reperfusion and the hearts were stained for αSMA, HA and Galectin-3. Here, expression of both α-SMA and HA was not significantly increased after 24 h in IL-23R-Y416FΔICD signaling deficient mice compared to IL-23R mice, however, a trend for increased αSMA was detected (Fig. 3C,D) . Staining of Galectin-3 also showed a trend for increased macrophage infiltration after 24 h of reperfusion in IL-23R-Y416FΔICD (Fig. 3E) . To assess the severity of myocardial tissue damage troponin T was measured in the serum of IL-23R-Y416FΔICD signaling deficient mice and IL-23R mice. No differences were observed among the different genotypes after 24 h of reperfusion (Fig. 3F ). Finally we analyzed the expression of genes by real-time PCR which are typically regulated early after closed-chest ischemia/reperfusion. Importantly, 24 h after reperfusion neither the inflammatory factors RORγt, IFNγ and IL-17α, nor the cell-cycle and anti-apoptotic factors CyclinD1, Bcl2l1 and Bcl2 or the structural proteins ColA1, Col3A1 and Acta1 (actin) were significantly differential regulated in IL-23R, IL-23R-Y416F and IL-23-Y416FΔICD signaling deficient mice (Fig. 4) . Again, only a trend towards increased expression of IFNγ, IL-17α and Col3A1 was observed in IL-23-Y416FΔICD signaling deficient mice as compared to wild-type mice. Surprisingly, our data indicated that abrogated IL-23 signaling has no effects on the outcome of close-chest LAD ischemia/reperfusion. This finding was not expected, since several groups have previously reported positive and negative effects of IL-23 signaling on permanent acute myocardial infarction in mice 4, 5 . Since the infarct sizes in closed-chest models are much smaller than in permanent occlusion of the LAD, we applied the alternative open-chest ischemia/reperfusion model in which the reperfusion can be visually inspected and which should give additional independent information about the role of IL-23 in ischemia/reperfusion. experiments with 50 min of ischemia and 4 weeks of reperfusion (Fig. 5A ). Here the LAD was occluded immediately after the ligature and reperfusion was initiated after 50 min. 5C  and D) . Also the quantification of myocardial infarct sizes showed no differences in both genotypes (Fig. 5E ). Before the mice were sacrificed, we performed MRI analysis after the injection of perfluorcarbon (F19) particles to quantify the phagocyte infiltration into the heart after 2 d of ischemia/reperfusion. As shown in Fig. 5F , a strong trend (p = 0.052) of increased F19 accumulation as indicator of infiltrating inflammatory phagocytes in the hearts of IL-23R-Y416FΔICD signaling deficient mice compared to IL-23R-wild-type mice was observed. Moreover, the interstitial space was determined 24 h after reperfusion by MRI and the extent of myocardial infarction was assessed. Here, we did not observe any differences in the infarct size in the hearts of IL-23R-Y416FΔICD signaling deficient mice compared to IL-23R-wild-type mice (Fig. 5G ).
Therapeutic treatment with IL-23 has no effect on the outcome of open-chest ischemia/reperfusion.
To investigate potential therapeutic effects of IL-23 on myocardial remodeling after I/R we treated C57/BL6 wild-type mice with HIL-23Fc or PBS as control. Therfore we generated Hyper-IL-23Fc (HIL-23Fc), consisting of p40 and p19 connected by a flexible peptide linker, fused to a Fc-tag (Fig. 6A) . For our studies we chose Hyper-IL-23Fc because it was shown that Hyper-cytokines are more active than the separate cytokine subunits 21 . In Hyper-cytokines, the cytokine subunits p19 and p40 are trapped in an active conformation by a flexible peptide linker. Moreover, the Fc-tag improved the stability of the protein and allowed a simple protein purification via ProteinA sepharose columns. To produce higher amounts of HIL-23Fc we first generated CHO-K1 cells that were stably expressing HIL-23Fc (Fig. 6B) . Second, HIL-23Fc was purified from CHO-K1 cell culture supernatants via ProteinA affinity chromatography (Fig. 6C) . Pure, recombinant HIL-23Fc was endotoxin-free confirmed by EndoZyme ® Detection Assay. Moreover, HIL-23Fc was highly biological active. As shown in Fig. 6D , half-maximal proliferation of IL-23-dependent Ba/F3-murine-IL-12Rβ1-murine-IL-23R cells was achieved with only 0.4 ng/ml HIL-23Fc, whereas no proliferation was inducible with green fluorescent protein (GFP) as control. HIL-23Fc-induced proliferation was specific, because Ba/F3-gp130 cells lacking the IL-23 receptor chains did not proliferate. Also analysis of signal transduction pathways in Ba/F3-mIL-12Rβ1/mIL-23R cells stimulated with HIL-23Fc demonstrated specificity and high activity of our recombinant Hyper IL-23Fc (Fig. 6E) .
Closed-chest LAD ischemia/reperfusion with 60 min ischemia and 3 weeks reperfusion was performed in C57/BL6 wild-type mice, which were treated with 10 µg/mouse HIL-23Fc diluted in sterile 200 µl PBS or as control injected with 200 µl sterile PBS intraperitoneally directly with onset of reperfusion and follow up on day 2, 4, 6 and 8. The left ventricle function was analyzed by echocardiography after 1 week and 3 weeks of I/R (Fig. 7A) . No statistical differences in ejection fraction, endsystolic volume and enddiastolic volume after 1 week and 3 weeks of reperfusion were detected in the IL-23 and control group (Fig. 7B) . To anylze the therapeutic effects of IL-23, mice were sacrificed and the ischemic hearts were taken 3 weeks after I/R and immunostaining of αSMA and HA was performed. The evaluations showed that in HIL-23Fc treated mice the amount of αSMA but not of HA was significantly decreased (Fig. 7C and D) . Furthermore, we quantified the infarct sizes in the HIL-23Fc-treated group and control-group and found no changes between both groups (Fig. 7E) . Our results showed that therapeutic treatment with IL-23 has no effects on the outcome of closed-chest LAD ischemia/reperfusion. Thus, we could not reproduce the negative effects of IL-23 on cardiac remodeling after I/R that was observed by two groups after IL-23 injection in rats 6, 22 .
Discussion
Taken together our study fails to reproduce the positive or negative effects of IL-23 on myocardial infarction despite using cutting-edge cardiovascular phenotyping by high resolution echocardiography and MRI. At this juncture, we can only speculate about the reasons, why we were not able to detect/reproduce a phenotype in IL-23R-Y416FΔICD signaling deficient mice after myocardial infarction. First of all, it became more and more clear that hygiene and housing conditions in the animal facilities have a major impact on the outcome of disease animal models and at least to some extent also on the clinical development success rates of novel drugs 23, 24 . Second, we used 50-60 min of ischemia followed by reperfusion which is a more clinical relevant model of acute myocardial infarction as compared to permanent ligation because in MI patients coronary blood flow is usually restored. Permanent ligation was, however, applied in all other studies with IL-23 deficient mice [4] [5] [6] 25 , but it causes also a milder disease formation with a limited loss of cardiac function, reduced cardiac remodeling and a less dynamic inflammatory response compared to ischemia/reperfusion models 26, 27 . Third, IL-23 biology is complex and deletion of IL-23p19 does not only affect IL-23 signaling but might also result in abrogation of IL-39 10 . Therefore deletion of the IL-23R which is the only signal-transducing receptor chain within the IL-23 receptor complex might have a different outcome as deletion of IL-23p19. Finally, IL-23 is a composite cytokine consisting of p19 and p40. p40 has at least two additional functions apart from its role as α-chain in IL-23. Together with p35, p40 forms also IL-12 9 . It might be possible that in the absence of p19, p40 might forms more IL-12. On the other hand, p40 has also immune-regulatory functions, most likely as a p40 homodimer. Interestingly, whereas IL-12 and IL-23 are pro-inflammatory cytokines, homodimeric p40 has anti-inflammatory function [28] [29] [30] . In the absence of p19, no pro-inflammatory IL-23 is produced but the surplus of free p40 might also contribute to phenotypes observed in IL-23p19 deficient mice. In conclusion, our data using the more clinically relevant LAD ischemia/reperfusion model demonstrated that IL-23 plays no role in myocardial infarction. 
Generation and genetic analysis of IL-23R-Y416F and IL-23R-Y416FΔICD mice. Floxed
IL-23R-Y416F mice were generated by ingenious targeting laboratory (www.genetargeting.com). The conditional targeting vector bearing the point mutation was electroporated in C57BL/6N embryonic stem cells. Targeted embryonic stem cells were microinjected into Balb/c blastocysts and resulting chimeras with a high percentage of black coat color were mated to wild-type C57BL/6N mice to generate F1 heterozygous offspring. Confirmed F1 heterozygotes were set up for mating with C57BL/6N FLP mice to generate somatic Neo deleted mice. Heterozygous mice were confirmed by PCR and mated to wild-type C57BL/6N mice to generated homozygous floxed IL-23R-Y416F mice. These mice were crossed with mice expressing Cre-recombinase under a human cytomegalovirus (CMV) minimal promotor 31, 32 . Human CMVCre +/− /IL-23R-Y416F −/+ mice were bred with IL-23R-Y416F mice. From the resulting offspring homozygous IL-23R-Y416F or homozygous IL-23R-Y416FΔICD mice were used for the experiments. DNA from tail clippings was isolated using the DirectPCR-Tail kit with proteinase K (Peqlab, Erlangen, Germany) following the manufactures instructions for 
Splenocyte culture. Spleen cells from 6 to 8-week-old IL-23R, IL-23R-Y416F and IL-23R-Y416FΔICD
mice were passed through a nylon mash into a 50 ml tube containing PBS. The cell suspension was centrifuged at 300 × g for 5 min at 4 °C. Splenocytes were incubated for 5 days with 10 µg/ml anti-CD3 (cat. MAB484) and 5 µg/ ml anti-CD28 (cat. AF483), in the absence or presence of 10 ng/ml human TGF-β1 (cat. 100-B), 40 ng/ml mouse IL-6 (cat. 406-ML) and 10 ng/ml mouse IL-1β (cat. 401-ML) (R&D Systems, Minneapolis, MN, USA) at 37 °C with 5% CO 2 . After 5 days, spleen cells were analyzed by flow cytometry and IL-17 concentrations in supernatants were determined by ELISA (cat. DY421, R&D Systems, Minneapolis, MN, USA). Closed and open-chest model of Ischemia/reperfusion injury. Ischemia followed by reperfusion was induced by closed-chest and open-chest model as described elsewhere 33, 34 . For closed-chest, 12-14 week old male mice were anesthetized by intraperitoneal injection of ketamine (60 mg/kg BW) and xylazine (10 mg/kg BW), intubated and connected to a rodent ventilator (Minivent Microventilator, Hugo Sachs, Germany). Body temperature was maintained at 37 °C via a heating plate. After precordial left lateral thoracotomy and pericardectomy, the LAD was identified and tunneled using a 0-7 prolene thread. After chest closure the ends of the thread were placed inside a subcutaneous pocket before closing of the skin and injection of buprenorphine (0.05-0.1 mg/ kg, s.c. every 8 h). At postoperative day 4, mice were anesthetized by inhalation of isoflurane 2.0 Vol%, the subcutaneous thread was retrieved and the LAD was occluded by cautiously pulling both ends apart. Continuous electrocardiogram (ECG) monitoring of ST elevations confirmed myocardial ischemia. After 60 min occlusion, tension was relieved, reperfusion was verified by ECG changes, and the thread was cut off at the chest wall before wound closure and injection of buprenorphine (0.05-0.1 mg/kg, s.c. every 8 h). Mice were sacrificed, serum was collected and hearts were harvested after 24 h, 4 days or 3 weeks of reperfusion.
Cell surface detection of IL-23R in IL-
For open-chest also 12-14 week old male mice were intubated and anesthetized by mechanical ventilation with isoflurane (2.0%) at a rate of 150 strokes/min and a tidal volume of 250-300 μl. Each animal was placed in a supine position with paws taped to an ECG board (leadII) to measure ST segment elevations during myocardial infarction. The chest was then opened with a lateral cut along the left side of the sternum. Subsequently, the pericardium was gently dissected to allow visualization of coronary artery anatomy. Ligation was proceeded with an 8-0 polypropylene suture with a tapered needle passed underneath the LAD, 1-3 mm from the tip of the left auricle. The success of infarction was verified microscopically by the absence of blood flow in the epicardium as well as significant elevations of ST segment. After 50 min, the snare occluder was opened to initiate reperfusion. The chest was then closed with 6-0 polypropylene suture with one layer through the muscle and a second layer through the skin and subcutaneous material. For analgesia, buprenorphine is administered half an hour before surgery and postoperatively (0.05-0.1 mg/kg, s.c. every 8 h up to 5 d). Mice were sacrificed and hearts were harvested after 4 weeks of reperfusion.
Echocardiography. For characterization of left ventricular (LV) function a Vevo 3100 High-Resolution
In Vivo Micro-Imaging System and a 30-MHz scanhead (VisualSonics Inc., Toronto, Canada) was used. Echocardiography was performed as previously described 35 . LV end-systolic volumes and end-diastolic volumes were measured and the ejection fractions were calculated. PFC injection. Mice were anesthetized with isoflurane (2.0%) using a home-built nose cone. A dosage of 0.6 mM/kg (for fluorescence experiments) or up to 3 mM/kg body weight (for MRI) of the PFC emulsion was given intravenously after 24 h of reperfusion.
Magnetic resonance imaging.
For cardiac analysis, data were recorded on a Bruker Avance III 9.4-T widebore (89 mm) NMR spectrometer operating at frequencies of 400.13 MHz for 1 H and 376.46 MHz for 19 F measurements as described 36, 37 . Experiments were performed using a Bruker microimaging unit (Micro 2.5) equipped with an actively shielded 40-mm gradient set (capable of 1500 mT/m maximum gradient strength and 110 μs rise time at 100% gradient switching, a 25-mm 1 H/ 19 F bird cage resonator and Paravision 5.1 as operating software). Mice were anesthetized with 1.5% isoflurane in a water-saturated gas mixture of 20% oxygen in nitrogen applied at a rate of 75 ml/min by manually restraining the animal and placing its head in a home-build nose cone. The frontpaws and the left hindpaw were attached to ECG electrodes (Klear-Trace, CAS Medical Systems, Branford). Respiration was monitored from a pneumatic pillow positioned at the animal's back. Vital functions were acquired by a M1025 system (SA Instruments, Stony Brook) and used to synchronize data acquisition with cardiac and respiratory motion. Throughout the experiment, mice were respiring spontaneously at a rate of approximately 100 min −1 and were kept at 37 °C.
Cardiac imaging. For functional analysis
1 H images of murine hearts were acquired using an ECG-and respiratory-triggered fast gradient echo cine sequence essentially as described 36, 37 37 . Affected volumes were calculated from 19 F images by planimetric analysis of PFC signals, multiplication with the slice thickness, and summation over all slices. In order to correct for differences in organ size obtained values were related to total heart volumes, which were assessed from the corresponding 1 H images.
19
F signal-to-noise ratios were determined from PFC signals originating from the myocardium only, and were averaged over the entire region containing PFCs. Signals derived from liver, chest, skull, lymph nodes or other tissues were not included into the calculation. Analysis of infarct size. Three and four weeks of reperfusion, animals were sacrificed and hearts were explanted for infarct size measurement. Formalin-fixed hearts were sliced in serial sections (level 1-5) and stained with Gomori's 1-step trichrome staining (Sigma Aldrich, Munich, Germany). For the quantification of infarct size in the left ventricle, 15 images of each were taken with the microscope (Keyence BZ-9000, Keyence Deutschland GmbH, Neu-Isenburg, Germany) from levels 2-5 in a 40-fold magnification and were quantified with ImageJ software (NIH, Bethesda, MD).
Serum biochemistry.
Gene expression analysis. RNA was isolated with TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. 5 µg RNA was used for cDNA synthesis using RevertAid reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) following manufacturer's instructions with standard oligo-dT method. Using SYBR ® Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA), the qPCR reaction was performed in triplicates using 25 ng of the cDNA as a template. The fluorescence detection and measurements were taken using ABI 7500 Real-Time PCR System (Applied Biosystems (Thermo Fisher Scientific, Waltham, MA, USA)). GAPDH was chosen as endogenous control. The primer pair's sequences are listed in Supplementary Table 2 .
Expression and purification of HIL-23Fc. Cloning of HIL-23Fc was described previously 39 . CHO-K1 cells (ACC-110, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) were transfected with TurboFect (Fermentas, Thermo Scientific). 48 h after transfection cells were split into fresh medium containing 1.125 mg/ml Geneticin ® (Genaxxon Bioscience GmbH, Ulm, Germany). Cells were fed with selective medium every 3-4 days until Geneticin ® -resistant foci were identified. Single colonies were picked, expanded in 96-well plates and analyzed by Western blot. High expressing clones were chosen for a second round of Geneticin ® selection to establish a stable CHO-K1 cell line. Cells were expanded and cultured in high glucose culture medium supplemented with 5% low ultra-low IgG fetal bovine serum (Gibco, Life Technologies, Darmstadt, Germany), 60 mg/liter penicillin, and 100 mg/liter streptomycin (Genaxxon Bioscience GmbH, Ulm, Germany) at 37 °C with 5% CO 2 . Supernatant was harvested by two-step centrifugation (15 min, 1000 × g, 15 min 10000 × g, 4 °C) and filtered through a 0.45 µm bottle top. HIL-23Fc was purified by Protein A agarose affinity chromatography. Hyper-IL-23Fc was eluted with 50 mM citrate buffer (50 mM citric acid, 50 mM sodium citrate), pH 3.25. HIL-23Fc was tested for endotoxins with EndoZyme ® Detection Assay (Hyglos GmbH,
